Basecare invites you to attend the lecture of “PGDIS Position Statement on the transfer of mosaic embryo 2019”
Pre-implantation genetic testing for aneuploidy (PGT-A) is mainly used to detect the embryos prior to transfer to eliminate those embryos with chromosomal abnormalities, and then screen the embryos with normal chromosomes for transplantation, finally achieving the goal of improving thesuccess rate of IVF.
Existing studies have shown that chromosome aneuploidy is the main cause of abortion and pregnancy failure. However, many aspects of this new technique are still controversial, especially regarding mosaic embryo transplantation. In recent years, with the continuous progress of cytogenetic,not only the whole chromosome of embryos can be screened, but also mosaic embryos can be detected.
Mosaic is the term assigned to embryos found to possess both normal and abnormal cells during pre-implantation genetic testing for aneuploidy (PGT-A) testing. What about the developmental potential of mosaic embryos? Throw it away? Or try a transplant? Is it possible for mosaic embryos to develop into healthy babies?
The pre-implantation genetic diagnosis international society (PGDIS) holds a conference every year to bring together experts from the fields of obstetrics and gynecology, reproductive health, embryology and human genetics to discuss the latest progress of PGT-A, which plays an important role in promoting the development of PGT-A technology. Professor David Cram, president of the international society for pre-implantation genetic diagnosis (PGDIS), is a world renowned geneticist and embryologist. At this lecture,Professor David Cram will discuss the grading and transplant recommendations of mosaic embryos of PGDIS. Welcome to join us.